Anixa Biosciences Inc (ANIX)

[zino]

achieved sensitivity of 92% and specificity of 92% for 88 patient samples,
On December 7, 2016, ITUS announced preliminary results from its Cchek™ cancer patient efficacy study. Using its most recent protocols and methods for measuring a patient’s immunological response to a malignancy, the Company achieved sensitivity of 92% and specificity of 92% for 88 patient samples, including 54 samples from patients with multiple types and severities of cancer, and 34 healthy patients.
http://ih.advfn.com/p.php?pid=nmona&article=74109620